Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Heat shock protein DNAJB8 is a novel target for immunotherapy of colon cancer-initiating cells.

Morita R, Nishizawa S, Torigoe T, Takahashi A, Tamura Y, Tsukahara T, Kanaseki T, Sokolovskaya A, Kochin V, Kondo T, Hashino S, Asaka M, Hara I, Hirohashi Y, Sato N.

Cancer Sci. 2014 Apr;105(4):389-95. doi: 10.1111/cas.12362. Epub 2014 Feb 24.

PMID:
24450541
2.

HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells.

Nishizawa S, Hirohashi Y, Torigoe T, Takahashi A, Tamura Y, Mori T, Kanaseki T, Kamiguchi K, Asanuma H, Morita R, Sokolovskaya A, Matsuzaki J, Yamada R, Fujii R, Kampinga HH, Kondo T, Hasegawa T, Hara I, Sato N.

Cancer Res. 2012 Jun 1;72(11):2844-54. doi: 10.1158/0008-5472.CAN-11-3062. Epub 2012 May 2.

PMID:
22552285
3.

Immune responses to human cancer stem-like cells/cancer-initiating cells.

Hirohashi Y, Torigoe T, Tsukahara T, Kanaseki T, Kochin V, Sato N.

Cancer Sci. 2016 Jan;107(1):12-7. doi: 10.1111/cas.12830. Epub 2015 Nov 12. Review.

PMID:
26440127
4.

Dnajb8, a Member of the Heat Shock Protein 40 Family Has a Role in the Tumor Initiation and Resistance to Docetaxel but Is Dispensable for Stress Response.

Yamashita M, Hirohashi Y, Torigoe T, Kusumoto H, Murai A, Imagawa T, Sato N.

PLoS One. 2016 Jan 11;11(1):e0146501. doi: 10.1371/journal.pone.0146501. eCollection 2016.

PMID:
26751205
5.

Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population.

Mori T, Nishizawa S, Hirohashi Y, Torigoe T, Tamura Y, Takahashi A, Kochin V, Fujii R, Kondo T, Greene MI, Hara I, Sato N.

Exp Mol Pathol. 2012 Feb;92(1):27-32. doi: 10.1016/j.yexmp.2011.09.016. Epub 2011 Oct 2.

PMID:
22001602
6.

Identification of antigenic peptides from novel renal cancer stem-like cell antigen, DNAJB8.

Nishizawa S, Hirohashi Y, Kusumoto H, Wakamiya T, Iguchi T, Yamashita S, Iba A, Kikkawa K, Kohjimoto Y, Torigoe T, Hara I.

Biochem Biophys Res Commun. 2017 Dec 16;494(3-4):693-699. doi: 10.1016/j.bbrc.2017.10.146. Epub 2017 Oct 28.

PMID:
29107688
7.

Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer-Initiating Cells and Is a Potent Target of Immunotherapy.

Morita R, Hirohashi Y, Torigoe T, Ito-Inoda S, Takahashi A, Mariya T, Asanuma H, Tamura Y, Tsukahara T, Kanaseki T, Kubo T, Kutomi G, Mizuguchi T, Terui T, Ishitani K, Hashino S, Kondo T, Minagawa N, Takahashi N, Taketomi A, Todo S, Asaka M, Sato N.

Clin Cancer Res. 2016 Jul 1;22(13):3298-309. doi: 10.1158/1078-0432.CCR-15-1709. Epub 2016 Feb 9.

PMID:
26861454
8.

Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is a novel target of lung cancer stem-like cell immunotherapy.

Horibe R, Hirohashi Y, Asano T, Mariya T, Suzuki T, Takaya A, Saijo H, Shionoya Y, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Watanabe K, Atsuyama E, Toji S, Hirano H, Hasegawa T, Takahashi H, Sato N, Torigoe T.

PLoS One. 2017 Mar 1;12(3):e0171460. doi: 10.1371/journal.pone.0171460. eCollection 2017.

PMID:
28248963
9.

Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.

Pan QZ, Pan K, Wang QJ, Weng DS, Zhao JJ, Zheng HX, Zhang XF, Jiang SS, Lv L, Tang Y, Li YQ, He J, Liu Q, Chen CL, Zhang HX, Xia JC.

Stem Cells. 2015 Feb;33(2):354-66. doi: 10.1002/stem.1850.

PMID:
25267273
10.

Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma.

Kano M, Tsukahara T, Emori M, Murase M, Torigoe T, Kawaguchi S, Wada T, Yamashita T, Sato N.

Cancer Sci. 2011 Aug;102(8):1443-7. doi: 10.1111/j.1349-7006.2011.01962.x. Epub 2011 May 31.

PMID:
21518139
11.

Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4.

Volonté A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G, Maccalli C.

J Immunol. 2014 Jan 1;192(1):523-32. doi: 10.4049/jimmunol.1301342. Epub 2013 Nov 25.

PMID:
24277698
12.

Dendritic cell-based immunotherapy for colon cancer using an HLA-A*0201-restricted cytotoxic T-lymphocyte epitope from tumor-associated antigen 90K.

Hee Lee J, Park MS, Hwang JE, Cho SH, Bae WK, Shim HJ, Kim DE, Chung IJ.

Cell Mol Immunol. 2013 May;10(3):275-82. doi: 10.1038/cmi.2012.74. Epub 2013 Mar 25.

PMID:
23524651
13.

Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines.

Liao T, Kaufmann AM, Qian X, Sangvatanakul V, Chen C, Kube T, Zhang G, Albers AE.

J Cancer Res Clin Oncol. 2013 Jan;139(1):159-70. doi: 10.1007/s00432-012-1311-2. Epub 2012 Sep 23.

PMID:
23001491
14.

Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells.

Inoda S, Hirohashi Y, Torigoe T, Morita R, Takahashi A, Asanuma H, Nakatsugawa M, Nishizawa S, Tamura Y, Tsuruma T, Terui T, Kondo T, Ishitani K, Hasegawa T, Hirata K, Sato N.

Am J Pathol. 2011 Apr;178(4):1805-13. doi: 10.1016/j.ajpath.2011.01.004.

PMID:
21435460
15.

Identification of cancer-stem cell antigens and development of CTL-mediated cancer immunotherapy.

Miyamoto S, Kanaseki T, Hirohashi Y, Tsukahara T, Kikuchi Y, Sato N, Torigoe T.

Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(1):40-47. doi: 10.2177/jsci.40.40. Review. Japanese.

PMID:
28539553
16.

Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene.

Yamada R, Takahashi A, Torigoe T, Morita R, Tamura Y, Tsukahara T, Kanaseki T, Kubo T, Watarai K, Kondo T, Hirohashi Y, Sato N.

Tissue Antigens. 2013 Jun;81(6):428-34. doi: 10.1111/tan.12113. Epub 2013 Apr 11.

PMID:
23574628
17.

Brother of the regulator of the imprinted site (BORIS) variant subfamily 6 is involved in cervical cancer stemness and can be a target of immunotherapy.

Asano T, Hirohashi Y, Torigoe T, Mariya T, Horibe R, Kuroda T, Tabuchi Y, Saijo H, Yasuda K, Mizuuchi M, Takahashi A, Asanuma H, Hasegawa T, Saito T, Sato N.

Oncotarget. 2016 Mar 8;7(10):11223-37. doi: 10.18632/oncotarget.7165.

PMID:
26849232
18.

Cellular stress induces cancer stem-like cells through expression of DNAJB8 by activation of HSF1.

Kusumoto H, Hirohashi Y, Nishizawa S, Yamashita M, Yasuda K, Murai A, Takaya A, Mori T, Kubo T, Nakatsugawa M, Kanaseki T, Tsukahara T, Kondo T, Sato N, Hara I, Torigoe T.

Cancer Sci. 2018 Jan 8. doi: 10.1111/cas.13501. [Epub ahead of print]

PMID:
29316077
19.

Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens.

Xu Q, Liu G, Yuan X, Xu M, Wang H, Ji J, Konda B, Black KL, Yu JS.

Stem Cells. 2009 Aug;27(8):1734-40. doi: 10.1002/stem.102.

PMID:
19536809
20.

Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells.

Hirohashi Y, Torigoe T, Inoda S, Takahashi A, Morita R, Nishizawa S, Tamura Y, Suzuki H, Toyota M, Sato N.

Immunotherapy. 2010 Mar;2(2):201-11. doi: 10.2217/imt.10.10. Review.

PMID:
20635928

Supplemental Content

Support Center